Ethical issues in international vaccine research and development. by Levine, Robert J.
In this discussion of the ethics of
multi-national vaccine trials, I will refer
primarily to the UNAIDS Guidance
Document, Ethical Considerations in HIV
Preventive Vaccine Research (hereafter,
Guidance Document) [1]. This document,
which was developed in the mid-1990s,
states that its scope is limited to multi-
national trials of HIV preventive vaccines.
However, I suggest that it is more general-
ly relevant to multinational trials, or devel-
opment programs, for vaccines. This
Guidance Document was influential in the
development of another major document
which provides ethical guidance and
direction for research involving humans as
subjects, the CIOMS† (Council of
International Organizations of Medical
Sciences) International Ethical Guidelines
for Biomedical Research Involving
Human Subjects (hereafter, International
Ethical Guidelines) [2] and, indirectly, the
World Medical Association’s Declaration
of Helsinki (hereafter, Helsinki) [3].
ETHICAL UNIVERSALISM VS.
CULTURAL PLURALISM
When one is working to develop ethi-
cal guidelines in the international arena,
one is immediately confronted with one of
the classical questions in ethics: Are ethics
universal or do they differ from one culture
to another? One might be able to escape
this question when working locally or
within the confines of a relatively homoge-
neous culture, but not in the international
context [4]. Ethical universalism is a posi-
tion that holds that ethics, or ethical princi-
ples, are the same in all places and in all
times. Universalists note that ethics seem
to be evolving over the years, but the peo-
ple who have a strong commitment to uni-
versalism hold that this is just an indication
that we’re getting closer and closer to the
universal truth. Cultural pluralism — in
contrast to universalism — notices that
ethics are, after all, developed in the course
of conversations within specific cultures,
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and traditions of those cultures. Cultural
pluralists conclude that differences in
ethics across cultures are both inevitable
and legitimate. Cultural pluralists some-
times refer to universalists with the deri-
sive term, ethical imperialists. Some uni-
versalists similarly disparage pluralists by
calling them ethical relativists.
My position is one of compromise: I
believetherearesomeethicalprinciplesthat
appear to be universal, particularly when
they are stated at a highly abstract level.
However, I believe that there is also a large
degree of legitimacy in cultural pluralism.
Even the universal ethical principles may be
interpreted very differently in diverse cul-
tures.Whatitmeanstoshowrespectforper-
sons in the United States may be vastly dif-
ferent from what it means in Sub-Saharan
Africa. Inmyownworkinthedevelopment
of international ethical codes and guide-
lines, I aspire to what I call “‘global applic-
ability.” That means that the guidelines are,
as far as we can tell, applicable currently in
all the cultures and societies in the world.
Thereisanassumptionthatwewillberevis-
ing these guidelines from time to time as
new understandings come to the fore.
SUBSTANTIVE AND PROCEDURAL
NORMS
A substantive norm is a rule that spec-
ifies what one should do because it is
morally right to do so; similarly, such rules
may specify what one should not do
because it is morally wrong to do so.
Procedural rules specify what procedures
one should follow. Some define the proce-
dures one should follow to determine what
to do when substantive rules do not give
clear guidance as to what specific behavior
is called for in a particular situation. Other
procedural rules provide support or assis-
tance as one attempts to comply with the
requirements of a substantive norm. An
example of the first type of procedural rule
is the requirement for review and approval
of all research proposals by an institutional
reviewboard(IRB);thepurposeofthispro-
cedure is to assure compliance with ethical
rules and to see to it that the requirements
of ethical norms are interpreted appropri-
ately in particular circumstances. The
requirement for a consent form is a proce-
dural norm of the second type; it helps the
investigator remember all the elements of
information that must be divulged during
the process of informed consent. (The
requirement for informed consent, itself, is
a substantive norm; it is required because it
is morally right to provide prospective sub-
jects with information that will empower
them to protect their own interests.)
When developing guidelines for rela-
tively homogeneous populations, one can
include a relatively large proportion of
substantive norms. Guidelines for hetero-
geneous populations, by contrast, are char-
acterized by a higher proportion of proce-
dural norms. It is much more difficult to
specify substantive norms when dealing
with the diversity of circumstances and
cultural traditions that globally applicable
guidelines must accommodate.
CAPACITY BUILDING
The UNAIDS Guidance Document
and the CIOMS International Ethical
Guidelines each devote considerable
attention to multinational research in
which the sponsors are located in the
wealthy industrialized countries and the
research subjects are in low-resource
countries; the latter are referred to as “host
countries.” The UNAIDS Guidance
Document insists that the research should
be limited to countries and communities
that have the capacity for independent sci-
entific and ethical review. It specifies that
“the capacity must be adequate before the
research begins” [1]. This, I believe, is an
“aspirational” standard. An aspirational
standard is one that we hope will be
applicable sometime in the future; we
must, however, acknowledge that this
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requirement is not in the CIOMS docu-
ment. Implicit in the CIOMS International
Ethical Guidelines is an understanding
that we should be striving in that direction.
Meanwhile, according to CIOMS
(Guideline 20), sponsors and investigators
from the wealthy industrialized countries
“have an ethical obligation to ensure that
biomedical research projects…contribute
effectively to national or local capacity to
design and conduct biomedical research,
and to provide scientific and ethical
review and monitoring of such research.
Capacity building may include, but is not
limited to…establishing and strengthening
ethical review processes/committees;
strengthening research capacity; develop-
ing technologies appropriate to health-care
and biomedical research; training of
research and health-care staff and educat-
ing the community from which research
subjects will be drawn” [2].
Capacity building is required to
ensure the scientific and ethical conduct of
research. It also should be designed to fos-
ter meaningful self-determination for the
communities in which the research is car-
ried out, as well as for the individuals who
serve as subjects. There is in all of the
international documents, a strong recom-
mendation that we should be striving to
develop partnerships of equals and that the
people from the wealthy industrial coun-
tries should be regarded as the moral
equals of those in the host countries.
COMMUNITY ENGAGEMENT
Engagement of the community is
designed to develop the vaccine develop-
ment program as a collaboration involving
the sponsors, investigators, community
leaders, prospective subjects, and other
stakeholders as appropriate. One major
goal of community engagement is to
ensure the acceptance of the research and
development by the community in which
the research is to be carried out. All
aspects of the research program are to be
discussed — even the scientific design of
the protocols. Opinions of the communi-
ty’s members about the scientific and
logistical features should be solicited and
the wishes of the primary stakeholders
should be accommodated to the extent this
is feasible without compromising scientif-
ic validity. There should be a discussion
leading to the design of risk reduction
interventions and the development of
effective methods of dissemination of
information about the trial. Community
engagement should also be designed to
develop the informed consent process, to
ensure equity in the choice of subjects, to
reach agreements regarding the standards
of care for research subjects who get sick
during the course of a clinical trial, and to
develop plans for the distribution of the
vaccine in case it proves to be suitably safe
and effective; the latter includes reaching
agreements about the meaning of “reason-
able availability” for the particular vaccine
development program (see below) (infra).
EARLY PHASE VACCINE TESTING
The 1993 version of the CIOMS
International Ethical Guidelines contained
a requirement that the early phases of vac-
cine research (phase one and perhaps
phase two) should be carried out in the
country of the sponsoring agency [5]. This
requirement was designed to protect the
low-resource countries and communities
from exploitation. Since the 1970s there
has been a general expectation reflected in
the ethical codes and guidelines that spe-
cial justifications are required to involve
vulnerable populations in research pro-
grams in which there are serious risks pre-
sented by interventions or procedures that
do not hold out the prospect of direct ben-
efit to the individual subjects [6]. Among
the special justifications that might be con-
sidered are that the strain or clade of virus
does not exist in the country of the spon-
sor, and the conduct of the early-phase
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country could be seen as a capacity-build-
ing experience to get the people in the host
country accustomed to doing this kind of
research.
The requirement to conduct early-
phase vaccine research in the country of
the sponsor was relaxed in the UNAIDS
Guidance Document and the 2002 revision
of the CIOMS International Ethical
Guidelines. This change was in response
to protests presented at the conferences
that led to the development of the
UNAIDS document. Participants from the
low-resource countries protested that the
CIOMS position on the developing coun-
tries was highly paternalistic. They
noticed, in particular, that the guidelines
for doing research in developing countries
looked almost exactly like the guidelines
for doing research involving children.
They argued that they were not to be treat-
ed as children. In particular, they should be
entitled to decide what sorts of research
will be carried out in their countries.
RESPONSIVENESS TO THE
HEALTH NEEDS AND PRIORITIES
OF THE HOST COUNTRY
Research carried out in a low-
resource country by sponsors and investi-
gators from the wealthy industrial coun-
tries must be responsive to the health needs
and priorities of the host country.This stan-
dard, which first appeared in the CIOMS
International Ethical Guidelines in 1993
[5], distinguishes health needs from priori-
ties. Health needs of a country could be
determined by an outside agency. This
agency could review epidemiological data
and decide that since many people are
afflicted by a certain disease, the country
“needs” a means to treat or prevent the dis-
ease. Priorities, by contrast, are determined
by the appropriate authorities within the
country. Such authorities may decide that
although the country has multiple “needs,”
they will assign a high priority to only one
or two. Decisions about priority must take
into account factors other than disease inci-
dence or prevalence such as limitations in
the country’s resources.
JUST DISTRIBUTION OF BENEFITS
The products of multinational
research carried out in low resource should
be made reasonably available to the resi-
dents of the host country., This concept
was introduced into international docu-
ments in the 1993 version of the CIOMS
International Ethical Guidelines [5]. It has
been included in subsequent promulga-
tions by UNAIDS, the World Medical
Association and CIOMS [1-3]. Originally,
it was designed to apply to the therapeutic,
diagnostic, or preventive products of the
research. Subsequently, it has been inter-
preted to mean as well the new knowledge
developed as a result of research. The rea-
sonable availability standard sounds fine
in the abstract; however, in particular
cases, it has been very difficult to decide
whether reasonable availability should
apply only to the individuals who partici-
pate as subjects in the trials, whether it
should apply more broadly to the entire
host community or country, or whether it
should apply to all populations at high risk
for developing whatever disease is the tar-
get of the research. Moreover, it remains to
be determined whether “reasonably avail-
able” could mean simply marketing the
product in the host country or making it
available at a price that is within the means
of the host country. Although we cannot
define what “reasonable availability”
means in general, there is a consensus that
its meaning within a particular research
context should be agreed in advance
among the primary stakeholders in the
research program; this agreement should
be negotiated during the process of com-
munity engagement.
“Sustainability” is another criterion
for ethical justification of research
designed to develop a therapeutic, diagnos-
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refers to the ability of the host country to
continue to make the product available to
the residents of the host country after the
research has been completed and the spon-
sors and investigators have departed, tak-
ing with them the extra funds and other
resources typically made available during
the conduct of the research. If the host
country cannot sustain the use of the prod-
uct, it is an indication that the researchers
may not have been adequately compliant
with the requirement for responsiveness to
the health needs of the country [7].
PLACEBO CONTROLS
Placebo controls are ethically accept-
able when there is no established vaccine
for the indication for which the candidate
vaccine is to be tested [1-3]. In some place-
bo-controlled vaccine trials, it may be
appropriate “to provide for those in the
‘control arm’ a vaccine that is unrelated to
the investigational vaccine” [2, Guideline
11]; for example, BCG. When there is an
established vaccine, one requires a com-
pelling reason to use placebo controls in a
new vaccine trial. Such reasons might be
that the established vaccine is not believed
to be effective against the strain of virus
that prevails in the host country, or con-
vincing evidence that the biological condi-
tions during the initial vaccine trial differ to
the extent that the results can not be applied
confidently in the new host country.
PROVISION OF HEALTH-CARE
SERVICES
According to the CIOMS International
Ethical Guidelines:
External sponsors of research are ethically
obliged to ensure the availability of health-
care services that are essential to the safe con-
duct of the research; treatment for subjects
who suffer injury as a consequence of
research interventions; and services that are a
necessary part of the commitment of a spon-
sor to make a beneficial intervention or prod-
uct developed as a result of the research rea-
sonably available to the population or com-
munity concerned [2, Guideline 21].
In the commentary on this guideline,
CIOMS states: “Although sponsors are, in
general, not obliged to provide health-care
services beyond that which is necessary
for the conduct of the research, it is moral-
ly praiseworthy to do so. Such services
typically include treatment for diseases
contracted in the course of the study. It
might, for example, be agreed to treat
cases of an infectious disease contracted
during a trial of a vaccine designed to pro-
vide immunity to that disease, or to pro-
vide treatment of incidental conditions
unrelated to the study….”
When prospective or actual subjects are found
to have diseases unrelated to the research, or
cannot be enrolled in a study because they do
not meet the health criteria, investigators
should, as appropriate, advise them to obtain,
or refer them for, medical care.
The UNAIDS Guidance Document
[1, Guidance point 16], in its specific con-
sideration of the development of HIV pre-
ventive vaccines, states that those who
become infected with HIV during the
course of a clinical trial should be treated
at one of three levels: 1) the level of care
that would be offered in the country of the
sponsor; 2) a level to be decided by the
host country; and 3) a level consistent with
that available in the host country.The level
to be employed in any particular trial
should be agreed during the process of
community engagement before the trial is
begun. It is not clear whether this guidance
is applicable to clinical trials of vaccines
other than those designed to prevent HIV
infection.
INFORMED CONSENT
In some cultures and societies,
informed consent may be problematic for
any of several reasons; the following are
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informed consent is unfamiliar because it
is not part of the customary interactions
between health-care professionals and
patients. Many or most of the prospective
subjects may be unfamiliar with such con-
cepts as cause and effect relationships,
contagion, placebos, randomization and
double-blind. In some communities, it is
required that an individual must have the
approval of a third party or of a group
before making the sorts of decisions
required in the process of informed con-
sent. These points notwithstanding,
UNAIDS [1, Guidance Points 12-15]
requires individual informed consent in
each case except when the subject is
incompetent or incapacitated; in such
cases third-party permission may be
acceptable. UNAIDS requires that the
process of informed consent be monitored.
CIOMS [(2]) similarly requires informed
consent or third-party permission; howev-
er, monitoring is not required.
SELECTION OF SUBJECTS
UNAIDS’s requirements for selection
of subjects in such a manner as to assure
the equitable distribution of risks and ben-
efits are generally harmonious with those
embodied in most contemporary ethical
codes and regulations. I will comment on
several distinctive features of these
requirements. First, as mentioned earlier,
“low-resource” or “technologically-
developing” countries are not to be regard-
ed as generally vulnerable. The devel-
oped/developing distinction:
…refers primarily to economic considera-
tions, which are not the only relevant factors
in HIV vaccine research. It also establishes
two fixed categories, whereas, in reality,
countries and communities are distributed
along a spectrum, characterized by a variety
of different factors that affect risk. It is more
useful to identify the particular aspects of a
social context that create conditions for
exploitation or increased vulnerability for the
pool of participants that has been selected [1,
Guidance Point 7].
“Women, including pregnant women,
potentially pregnant women and breast-
feeding women, should be eligible for
enrolment in HIV preventive vaccine tri-
als, both as a matter of equity and because
in many communities throughout the
world women are at high risk of HIV
infection” [1, Guidance point 17].
Similarly, “Children, including infants and
adolescents” should be eligible for enrol-
ment [1, Guidance point 18].
ECONOMIC CONSIDERATIONS
Several features of these guidelines
create a potential for serious economic dis-
tortions. For example, provision of free
medical services may be seen as an undue
inducement to subjects, as well as to the
host country. Often in the course of a clin-
ical trial of a new vaccine, subjects receive
medical goods and services that they sim-
ply would not get in the absence of
research. Sometimes the research sponsor
develops elaborate facilities to provide
health care during the course of the
research; local health authorities see this
as an opportunity to redirect their efforts
and resources. Then, when the research
has been completed and the sponsors and
investigators leave, the people of the com-
munity are even worse off than they were
before the trial started because they do not
even have what they had before the min-
istry of health withdrew its resources.
Sponsors and investigators must be careful
not to leave the host country worse off
than it was before the research program
began.
The requirement for reasonable avail-
ability may also be seen as an undue
inducement both to the subjects and to the
country. How else could residents of some
Sub-Saharan countries be assured of con-
tinuing access to a vaccine or a drug that
costs more than the annual per capita
health budget in that country? Reasonable
availability may also have an effect on the
sponsor. If the reasonable availability stan-
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developed product reasonably available to
all persons residing in the country, the pru-
dent sponsor would very much prefer to
conduct the research program in countries
with relatively small populations.
CLOSING COMMENT
The distribution of wealth among the
nations of the world is clearly inequitable.
There is a temptation to use international
research documents as devices to correct
inequities. And I believe that, to some
extent, this is a reasonable and construc-
tive activity. However, I also believe that
we must avoid the development of guide-
lines that would impede the efforts of
sponsors and investigators in industrial-
ized countries to assist countries with less-
er resources in their efforts to develop
treatments and preventions that they can
afford.
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